@drrickbarnett @maiasz Vivitrol or naltrexone should not be classed with agonists or partial agonists. May work for a few, often coercive. It offers no protection should people stop & reinitiate- it increases risk with super sensitisation https://t.co/
@borousk @DrewTurner73 @US_FDA Nobody said it was while actually on it, so you’ll be waiting a while. https://t.co/sp47KxgdiM
@maiasz @D_Winetsky_MD Absolutely. Even the existing reports indicate the potentiation problem is under-appreciated https://t.co/drPIteFOkC
@howell_ben @TruMedicines Not the only medication approved by the FDA but where questions about effectiveness persist. FDA approval process can and is gamed. This is why we have to double (triple, quadruple) down on post-marketing surveillance see also h